Navid Hafez, MD, MPH < Yale School of ...

Dr. Navid Hafez, MD

Claim this profile

Yale University

Expert in Cystic Tumor
Studies Cancer
13 reported clinical trials
34 drugs studied

Area of expertise

1Cystic Tumor
Global Leader
Navid Hafez, MD has run 11 trials for Cystic Tumor. Some of their research focus areas include:
Stage IV
Stage III
KRAS positive
2Cancer
Navid Hafez, MD has run 8 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage III
KRAS positive

Affiliated Hospitals

Image of trial facility.
Yale University
Image of trial facility.
The Angeles Clinic And Research Institute - West Los Angeles Office

Clinical Trials Navid Hafez, MD is currently running

Image of trial facility.

Ipatasertib + Chemotherapy

for Cancer

This phase II ComboMATCH treatment trial tests the usual treatment of chemotherapy (paclitaxel) plus ipatasertib in patients with solid tumor cancers that that cannot be removed by surgery (unresectable), has spread to nearby tissue or lymph nodes (locally advanced) or from where it first started (primary site) to other places in the body (metastatic), and has PTEN and AKT genetic changes. Chemotherapy drugs, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Targeted therapy, such as Ipatasertib, may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. The addition of ipatasertib to paclitaxel in solid tumors with PTEN and AKT genetic changes could increase the percentage of tumors that shrink as well as lengthen the time that the tumors remain stable (without progression). Researchers hope to learn if paclitaxel plus ipatasertib will shrink this type of cancer or stop its growth.
Recruiting1 award Phase 2
Image of trial facility.

Nivolumab

for Cancer

This phase Ib trial studies the side effects of nivolumab and to see how well it works in treating patients with autoimmune disorders and cancer that has spread to other places in the body or cannot removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Recruiting1 award Phase 120 criteria

More about Navid Hafez, MD

Clinical Trial Related7 years of experience running clinical trials · Led 13 trials as a Principal Investigator · 6 Active Clinical Trials
Treatments Navid Hafez, MD has experience with
  • Pembrolizumab
  • Olaparib
  • Paclitaxel
  • Sotorasib
  • Ipatasertib
  • Palbociclib

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Navid Hafez, MD specialize in?
Is Navid Hafez, MD currently recruiting for clinical trials?
Are there any treatments that Navid Hafez, MD has studied deeply?
What is the best way to schedule an appointment with Navid Hafez, MD?
What is the office address of Navid Hafez, MD?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security